Drug Type Small molecule drug |
Synonyms Nezulcitinib |
Mechanism JAK1 inhibitors(Tyrosine-protein kinase JAK1 inhibitors), JAK2 inhibitors(Tyrosine-protein kinase JAK2 inhibitors), JAK3 inhibitors(Tyrosine-protein kinase JAK3 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Molecular FormulaC30H37N7O2 |
InChIKeyVQIIUJSNIKEMCK-MHZLTWQESA-N |
CAS Registry2412496-23-0 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Fibrosis | Phase 2 | US | 05 Sep 2022 | |
Acute Lung Injury | Phase 2 | US | 24 Jun 2020 | |
Acute Lung Injury | Phase 2 | BR | 24 Jun 2020 | |
Acute Lung Injury | Phase 2 | FI | 24 Jun 2020 | |
Acute Lung Injury | Phase 2 | MD | 24 Jun 2020 | |
Acute Lung Injury | Phase 2 | RO | 24 Jun 2020 | |
Acute Lung Injury | Phase 2 | UA | 24 Jun 2020 | |
Acute Lung Injury | Phase 2 | GB | 24 Jun 2020 | |
COVID-19 | Phase 2 | US | 24 Jun 2020 | |
COVID-19 | Phase 2 | BR | 24 Jun 2020 |
Phase 2 | 205 | yrfpauuexw(apodtzmjud) = vzmvevxcoe mpzcifxvfa (ilgrphuhws ) | - | 01 Jul 2023 | |||
Placebo | yrfpauuexw(apodtzmjud) = xrayfveuax mpzcifxvfa (ilgrphuhws ) | ||||||
Phase 1 | 24 | uionvnmnsm(jxhypivfbo) = btmauitgid pxdbqwfwph (khnzhzeejj ) | Positive | 01 Nov 2021 | |||
Placebo | uionvnmnsm(jxhypivfbo) = otjbzgwugw pxdbqwfwph (khnzhzeejj ) | ||||||
Phase 2 | 200 | mpfntfqbgr(devwngvdpo) = tzsxeniwhb sduxayfvfn (aokpwyqagr ) View more | Negative | 21 Jun 2021 | |||
Placebo | mpfntfqbgr(devwngvdpo) = sgdbbbyglk sduxayfvfn (aokpwyqagr ) View more |